BioNTech and Pfizer will start a clinical trial of a Covid-19 vaccine adapted to the BA.4 and BA.5 variants of Omicron this month, as the German biotech forecasts an increase in demand at the end of the year.
BioNTech和辉瑞(Pfizer)一款针对Omicron BA.4和BA.5亚型变体毒株的新冠疫苗将在本月投入临床试验。BioNTech预计年底需求将会增加。
您已阅读6%（289字），剩余94%（4305字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。